Socio-demographic and cultural factors related to non-participation in the Dutch colorectal cancer screening programme

BackgroundHigh participation rates are essential for a screening programme to be beneficial. To reach non-participants in a targeted manner, insight in characteristics of non-participants is needed. We investigated demographic differences between participants and non-participants in the Dutch faecal immunochemical test-based colorectal cancer (CRC) screening programme.MethodsIn this population-based cohort study, we included all invitees for CRC screening in 2018 and 2019. Participation status, birth year, and sex were extracted from the Dutch national screening information system and linked to demographic characteristics from Statistics Netherlands, including migration background, level of education, socioeconomic category, household composition, and household income. A multivariable logistic regression was used to assess the association between demographic factors and participation.ResultsA total of 4,383,861 individuals were invited for CRC screening in 2018 and 2019, of which 3,170,349 (72.3%) participated. Individuals were less likely to participate when they were single and/or living with others (single with other residents versus couple: odds ratio [OR] 0.34, 95% confidence interval [CI]: 0.31–0.38), had a migration background (e.g. Moroccan migrant versus Dutch background: OR 0.43, 95% CI: 0.42–0.44), or had a low income (lowest versus highest quintile: OR 0.45, 95% CI: 0.44–0.45). Although to a lesser extent, non-participation was also significantly associated with being male, being younger, receiving social welfare benefits and having a low level of education.ConclusionWe found that individuals who were single and/or living with others, immigrants from Morocco or individuals with low income were the least likely to participate in the Dutch CRC screening programme. Targeted interventions are needed to minimise inequities in CRC screening.Cellular mechanisms in basic and clinical gastroenterology and hepatolog

The MUSE-Faint survey: IV. Dissecting Leo T, a gas-rich relic with recent star formation

Galaxie

Suppression of HBV by Tenofovir in HBV/HIV coinfected patients : a systematic review and meta-analysis

Background: Hepatitis B coinfection is common in HIV-positive individuals and as antiretroviral therapy has made death due to AIDS less common, hepatitis has become increasingly important. Several drugs are available to treat hepatitis B. The most potent and the one with the lowest risk of resistance appears to be tenofovir (TDF). However there are several questions that remain unanswered regarding the use of TDF, including the proportion of patients that achieves suppression of HBV viral load and over what time, whether suppression is durable and whether prior treatment with other HBV-active drugs such as lamivudine, compromises the efficacy of TDF due to possible selection of resistant HBV strains. Methods: A systematic review and meta-analysis following PRISMA guidelines and using multilevel mixed effects logistic regression, stratified by prior and/or concomitant use of lamivudine and/or emtricitabine. Results: Data was available from 23 studies including 550 HBV/HIV coinfected patients treated with TDF. Follow up was for up to seven years but to ensure sufficient power the data analyses were limited to three years. The overall proportion achieving suppression of HBV replication was 57.4%, 79.0% and 85.6% at one, two and three years, respectively. No effect of prior or concomitant 3TC/FTC was shown. Virological rebound on TDF treatment was rare. Interpretation: TDF suppresses HBV to undetectable levels in the majority of HBV/HIV coinfected patients with the proportion fully suppressed continuing to increase during continuous treatment. Prior treatment with 3TC/FTC does not compromise efficacy of TDF treatment. The use of combination treatment with 3TC/FTC offers no significant benefit over TDF alone

The MUSE-Faint survey: III. Constraining scalar field dark matter with Antlia B

Galaxie

The MUSE-Faint survey. IV. Dissecting Leo T, a gas-rich relic with recent star formation

Context. Leo T (MV = −8.0) is a peculiar dwarf galaxy that stands out for being both the faintest and the least massive galaxy known to contain neutral gas and to display signs of recent star formation. It is also extremely dark-matter dominated. As a result, Leo T presents an invaluable opportunity to study the processes of gas and star formation at the limit where galaxies are found to have rejuvenating episodes of star formation. Aims. Our approach to studying Leo T involves analysing photometry and stellar spectra to identify member stars and gather information about their properties, such as line-of-sight velocities, stellar metallicities, and ages. By examining these characteristics, we aim to better understand the overall dynamics and stellar content of the galaxy and to compare the properties of its young and old stars. Methods. Our study of Leo T relies on data from the Multi Unit Spectroscopic Explorer (MUSE) on the Very Large Telescope, which we use to identify 58 member stars of the galaxy. In addition, we supplement this information with spectroscopic data from the literature to bring the total number of member stars analysed to 75. To further our analysis, we complement these data with Hubble Space Telescope (HST) photometry. With these combined datasets, we delve deeper into the galaxy’s stellar content and uncover new insights into its properties. Results. Our analysis reveals two distinct populations of stars in Leo T. The first population, with an age of ≲ 500 Myr, includes three emission-line Be stars comprising 15% of the total number of young stars. The second population of stars is much older, with ages ranging from > 5 Gyr to as high as 10 Gyr. We combine MUSE data with literature data to obtain an overall velocity dispersion of σv = 7.07+1.29 −1.12 km s−1 for Leo T. When we divide the sample of stars into young and old populations, we find that they have distinct kinematics. Specifically, the young population has a velocity dispersion of 2.31+2.68 −1.65 km s−1 , contrasting with that of the old population, of 8.14+1.66 −1.38 km s−1 . The fact that the kinematics of the cold neutral gas is in good agreement with the kinematics of the young population suggests that the recent star formation in Leo T is linked with the cold neutral gas. We assess the existence of extended emission-line regions and find none to a surface brightness limit of < 1 × 10−20 erg s−1 cm−2 arcsec−2 which corresponds to an upper limit on star formation of ∼ 10−11 M⊙ yr−1 pc−2 , implying that the star formation in Leo T has ended

Human fetal brain self-organizes into long-term expanding organoids

Human brain development involves an orchestrated, massive neural progenitor expansion while a multi-cellular tissue architecture is established. Continuously expanding organoids can be grown directly from multiple somatic tissues, yet to date, brain organoids can solely be established from pluripotent stem cells. Here, we show that healthy human fetal brain in vitro self-organizes into organoids (FeBOs), phenocopying aspects of in vivo cellular heterogeneity and complex organization. FeBOs can be expanded over long time periods. FeBO growth requires maintenance of tissue integrity, which ensures production of a tissue-like extracellular matrix (ECM) niche, ultimately endowing FeBO expansion. FeBO lines derived from different areas of the central nervous system (CNS), including dorsal and ventral forebrain, preserve their regional identity and allow to probe aspects of positional identity. Using CRISPR-Cas9, we showcase the generation of syngeneic mutant FeBO lines for the study of brain cancer. Taken together, FeBOs constitute a complementary CNS organoid platform.</p

Endoscopic sphincterotomy to prevent post-ERCP pancreatitis after self-expandable metal stent placement for distal malignant biliary obstruction (SPHINX): a multicentre, randomised controlled trial

Background: Endoscopic retrograde cholangiopancreatography (ERCP) with fully covered self-expandable metal stent (FCSEMS) placement is the preferred approach for biliary drainage in patients with suspected distal malignant biliary obstruction (MBO). However, FCSEMS placement is associated with a high risk of post-ERCP pancreatitis (PEP). Endoscopic sphincterotomy prior to FCSEMS placement may reduce PEP risk. Objective: To compare endoscopic sphincterotomy to no sphincterotomy prior to FCSEMS placement. Design: This multicentre, randomised, superiority trial was conducted in 17 hospitals and included patients with suspected distal MBO. Patients were randomised during ERCP to receive either endoscopic sphincterotomy (sphincterotomy group) or no sphincterotomy (control group) prior to FCSEMS placement. The primary outcome was PEP within 30 days. Secondary outcomes included procedure-related complications and 30-day mortality. An interim analysis was performed after 50% of patients (n=259) had completed follow-up. Results: Between May 2016 and June 2023, 297 patients were included in the intention-to-treat analysis, with 156 in the sphincterotomy group and 141 in the control group. After the interim analysis, the study was terminated prematurely due to futility. PEP did not differ between groups, occurring in 26 patients (17%) in the sphincterotomy group compared with 30 patients (21%) in the control group (relative risk 0.78, 95% CI 0.49 to 1.26, p=0.37). There were no significant differences in bleeding, perforation, cholangitis, cholecystitis or 30-day mortality. Conclusion: This trial found that endoscopic sphincterotomy was not superior to no sphincterotomy in reducing PEP in patients with distal MBO. Therefore, there was insufficient evidence to recommend routine endoscopic sphincterotomy prior to FCEMS placement. Trial registration number: NL5130